by ElasmoAdm1n | Mar 5, 2025 | News
DR OBINNA C UBAH (Principal Scientist and Future Leaders Fellow (UKRI)) who leads our autoimmune inflammatory disease team is presenting new data on our lead first in class drug conjugate, ELN 28. His poster entitled, “Development and functional characterisation...
by ElasmoAdm1n | Dec 4, 2024 | News
It was fantastic to welcome and support Advanced Higher Biology pupils from Harlaw Academy again. The day began with some information about Elasmogen and drug discovery, followed by engaging discussions about two fundamental laboratory techniques and hands-on...
by ElasmoAdm1n | Jun 4, 2024 | News
Almac Discovery, a research driven drug discovery company and member of the Almac Group, has announced the nomination of a new pre-clinical candidate molecule (ALM-401), a First in Class Bispecific Antibody Drug Conjugate (ADC) for the treatment of refractory lung...
by ElasmoAdm1n | Apr 7, 2024 | News
Hear from Elasmogen’s CEO, Prof. Caroline Barelle, how The Scottish National Investment Bank helps to develop next-generation therapeutic drugs, with the potential to improve the health of people in Scotland and...
by ElasmoAdm1n | Jun 20, 2023 | News
Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC Brewin Dolphin. Please see here the link to the story.
by ElasmoAdm1n | Apr 28, 2023 | News
Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new investment from BGF, The Bank and Scottish Enterprise who joined existing investors, Deepbridge...
